Small bronchoscopic biopsy specimens for detecting EGFRgene mutations in advanced lung adenocarcinoma

Yunqiang Nie, Cui-yun Li, Na Li, Xiaoying Zhang, Hui Wang, Da-cai Guo, P. Han, Xin Lü, Shulan Liu, Changzheng Wang, Xinyi Xu
{"title":"Small bronchoscopic biopsy specimens for detecting EGFRgene mutations in advanced lung adenocarcinoma","authors":"Yunqiang Nie, Cui-yun Li, Na Li, Xiaoying Zhang, Hui Wang, Da-cai Guo, P. Han, Xin Lü, Shulan Liu, Changzheng Wang, Xinyi Xu","doi":"10.3724/SP.J.1008.2015.00049","DOIUrl":null,"url":null,"abstract":"Objective To examine epidermal growth factor receptor(EGFR)gene mutations in small bronchoscopic biopsy specimens,so as to provide guidance for clinical targeted therapy.Methods Fifty-six female patients with advancedstage Ⅲ B-Ⅳ lung adenocarcinoma underwent endoscopic endobronchial biopsy of tumor tissues or transbronchial needle aspiration of mediastinal and hilar lymph nodes.Under the endoscope,20 patients underwent only bronchial biopsy,28 underwent only transbronchial needle aspiration(TBNA)lymph node biopsy,and 8underwent both endobronchial biopsy and TBNA biopsy of mediastinal and hilar lymph nodes.A total of 64 specimens were collected and were subjected to detection of EGFR gene mutations after confirmation of lung adenocarcinoma.The specimens were then divided into endobronchial metastasis group and lymph node metastasis group,and the mutations of exons 19 and 21were detected and the clinical efficacy of targeted therapy was analyzed.Results Exon 19 had higher positive rate in the endobronchial metastasis group(χ2=4.304,P=0.038),and exon 21 had higher positive rate in lymph node metastasis group(χ2=18.727,P=0.000).A total of 24 cases were included for the clinical efficacy assessments:10had endobronchial metastasis(exon 19 mutations in 8cases,21 exon in 2cases),with the disease control rate being 90%(9/10)and median progression-free survival period being 14.8 months;14patients had lymph node metastasis(19exon 3cases,21 exon 11cases),with the disease control rate being 78.57%(11/14)and the median progression-free survival period being 9.2 months;the disease control rates were not significantly different between the two groups(P0.05)and the median progression-free survival periods were significantly different between the two groups(χ2= 4.134,P=0.042).Conclusion Mutations of different EGFRexons might relate to the metastasis forms of female advanced lung adenocarcinoma,with exon 19 prone to endobronchial metastasis and exon 21 to lymph node metastasis.Targeted therapy for patients with endobronchial metastasis has a better outcome than that for patients with lymph node metastasis.","PeriodicalId":6893,"journal":{"name":"第二军医大学学报","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"第二军医大学学报","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3724/SP.J.1008.2015.00049","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To examine epidermal growth factor receptor(EGFR)gene mutations in small bronchoscopic biopsy specimens,so as to provide guidance for clinical targeted therapy.Methods Fifty-six female patients with advancedstage Ⅲ B-Ⅳ lung adenocarcinoma underwent endoscopic endobronchial biopsy of tumor tissues or transbronchial needle aspiration of mediastinal and hilar lymph nodes.Under the endoscope,20 patients underwent only bronchial biopsy,28 underwent only transbronchial needle aspiration(TBNA)lymph node biopsy,and 8underwent both endobronchial biopsy and TBNA biopsy of mediastinal and hilar lymph nodes.A total of 64 specimens were collected and were subjected to detection of EGFR gene mutations after confirmation of lung adenocarcinoma.The specimens were then divided into endobronchial metastasis group and lymph node metastasis group,and the mutations of exons 19 and 21were detected and the clinical efficacy of targeted therapy was analyzed.Results Exon 19 had higher positive rate in the endobronchial metastasis group(χ2=4.304,P=0.038),and exon 21 had higher positive rate in lymph node metastasis group(χ2=18.727,P=0.000).A total of 24 cases were included for the clinical efficacy assessments:10had endobronchial metastasis(exon 19 mutations in 8cases,21 exon in 2cases),with the disease control rate being 90%(9/10)and median progression-free survival period being 14.8 months;14patients had lymph node metastasis(19exon 3cases,21 exon 11cases),with the disease control rate being 78.57%(11/14)and the median progression-free survival period being 9.2 months;the disease control rates were not significantly different between the two groups(P0.05)and the median progression-free survival periods were significantly different between the two groups(χ2= 4.134,P=0.042).Conclusion Mutations of different EGFRexons might relate to the metastasis forms of female advanced lung adenocarcinoma,with exon 19 prone to endobronchial metastasis and exon 21 to lymph node metastasis.Targeted therapy for patients with endobronchial metastasis has a better outcome than that for patients with lymph node metastasis.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
小支气管镜活检标本用于检测晚期肺腺癌中EGFRgene突变
目的探讨小支气管镜活检标本中表皮生长因子受体(EGFR)基因突变情况,为临床靶向治疗提供指导。方法对56例晚期ⅢB-Ⅳ女性肺腺癌患者行内镜下支气管内活检或纵隔、肺门淋巴结穿刺活检。内镜下,20例患者仅行支气管活检,28例患者仅行经支气管穿刺活检(TBNA)淋巴结活检,8例患者同时行纵隔和肺门淋巴结支气管活检和TBNA活检。共采集标本64例,确诊肺腺癌后进行EGFR基因突变检测。将标本分为支气管内转移组和淋巴结转移组,检测19、21外显子的突变情况,分析靶向治疗的临床疗效。结果外显子19在支气管内转移组阳性率较高(χ2=4.304,P=0.038),外显子21在淋巴结转移组阳性率较高(χ2=18.727,P=0.000)。临床疗效评估共纳入24例:支气管内转移10例(外显子19突变8例,外显子21例),疾病控制率为90%(9/10),中位无进展生存期为14.8个月;淋巴结转移14例(外显子3 19例,外显子11 21例),疾病控制率为78.57%(11/14),中位无进展生存期为9.2个月,两组疾病控制率无显著差异两组间无进展生存期中位数差异有统计学意义(χ2= 4.134,P=0.042)。结论不同EGFRexons的突变可能与女性晚期肺腺癌的转移形式有关,其中外显子19易发生支气管内转移,外显子21易发生淋巴结转移。支气管内转移患者的靶向治疗效果优于淋巴结转移患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
第二军医大学学报
第二军医大学学报 Medicine-Medicine (all)
CiteScore
0.50
自引率
0.00%
发文量
14752
期刊介绍: Founded in 1980, Academic Journal of Second Military Medical University(AJSMMU) is sponsored by Second Military Medical University, a well-known medical university in China. AJSMMU is a peer-reviewed biomedical journal,published in Chinese with English abstracts.The journal aims to showcase outstanding research articles from all areas of biology and medicine,including basic medicine(such as biochemistry, microbiology, molecular biology, genetics, etc.),clinical medicine,public health and epidemiology, military medicine,pharmacology and Traditional Chinese Medicine),to publish significant case report, and to provide both perspectives on personal experiences in medicine and reviews of the current state of biology and medicine.
期刊最新文献
Reliability and validity of the Chinese version of fear of coronavirus disease 2019 scale Bat-related coronavirus Infection control in coronavirus disease 2019 wards of Wuhan Huoshenshan Hospital Effectiveness of anti-pressure protective mask for medical personnel fighting against coronavirus disease 2019 The status of grief counseling among front-line nurses during the coronavirus disease 2019 epidemic
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1